JSKN003
HER2-expressing cancers
Phase 1/2Active
Key Facts
About AlphaMab Oncology
AlphaMab Oncology develops innovative bispecific antibodies and ADCs for cancer treatment using proprietary glycan-specific conjugation and CRIB platforms.
View full company profile